Management of glucocorticoids-induced osteoporosis: role of teriparatide

Silvia Migliaccio¹
Marina Brama¹
Nazzarena Malavolta²
¹Dipartimento di Fisiopatologia Medica, Policlinico Umberto I, Università degli Studi Sapienza di Roma, Italy; ²Dipartimento di Medicina Interna, Policlinico S Orsola Malpighi, Bologna, Italy

Abstract: Glucocorticoids (GC)-induced osteoporosis (GIOP) is the most common cause of secondary osteoporosis, which leads to an increased fracture risk in patients. The normal bone turnover depends on a balance between osteoblasts and osteoclasts activity and GC can cause a rapid bone loss, decreasing bone formation and increasing bone resorption. The decreased bone formation is mainly due to the GC-induced apoptosis of both osteoblasts and osteocytes, while the increased bone resorption is due to the increased life-span of pre-existing osteoclasts. Bisphosphonates are clearly effective in preventing and treating GIOP but anabolic therapeutic strategies are the new promising therapeutic alternative. Experimental and clinical studies indicate that teriparatide, the active (1–34) parathyroid hormone (PTH) molecule, is efficacious for the treatment of GIOP, being able to induce an increase in bone mass in these patients. Intermittent administration of human PTH (1–34) stimulates bone formation by increasing osteoblast number. Additionally, human PTH (1–34) modulates the level and/or activity of locally produced growth factors and cytokines. Teriparatide has been demonstrated in several clinical studies to significantly decrease the incidence of fractures in patients affected by GIOP. It has recently received an indication for GIOP and its label indication has also been expanded.

Keywords: glucocorticoids, osteoblasts, osteoclasts, osteoporosis, teriparatide

Introduction

Early last century Cushing described the negative effect of hypercortisolism on the skeleton.¹ Nowadays secondary forms, due to pharmacological use of glucocorticoids (GC), are the most frequent forms of an excess of these hormones.²–⁶ GC are the most widely used therapy in medicine and long-term use is characterized by a significant alteration of bone tissue, named GC-induced osteoporosis (GIOP), which is a metabolic bone disease characterized by decreased skeletal strength with an increased fracture risk.⁴ The GC-induced bone loss is dose-dependent, but it can also be present with long-term low dosage treatments.³–⁶ Indeed, the loss of bone mass occurs in a biphasic manner with a fast decrease at the beginning of therapy (loss of 12% in the first year) and a slower decrease after then (3%).⁷–⁸ GIOP must be considered a serious pathological condition because of the high number of patients who use these molecules to treat many different chronic diseases.⁹

As first described by Cushing, GIOP affects both trabecular and cortical bone and a vertebral fracture can be the first symptom of the disease.¹,⁹,¹⁰

Although the clinical manifestations of GC therapy have been known since the early 20th century,¹–⁶ the cellular and molecular mechanisms of skeletal alterations are not yet fully known. Some data suggest that alterations in hormonal levels might play a role in the calcium–phosphorus homeostasis (Table 1); however, GC exert a direct receptor-mediated effect on bone cells, leading to an altered bone remodeling.¹¹

Indeed, bone tissue is a metabolically active organ undergoing continuous remodeling throughout life, which serves to adjust bone architecture to meet mechanical
Therapeutic perspectives

As mentioned above, because GIOP is a severe condition which leads to an increased fracture risk within the first months of therapy,

efficacious therapies are needed to counter their deleterious effects on the skeleton. Although bisphosphonates have been demonstrated to be an efficacious therapy for both prevention and cure of GIOP,

the new bone anabolic agent teriparatide is a highly promising and interesting molecule for the treatment of GIOP.

Mechanisms of action of teriparatide

The beneficial effects of daily injection of human parathyroid hormone (PTH) amino-terminal peptide 1–34, teriparatide, have been shown in randomized, placebo-controlled trials in postmenopausal women, and in elderly men and in women with GIOP.

Osteoblasts, bone lining cells, and bone marrow stromal cells have PTH receptors, and intermittent PTH stimulates these cells through the modulation of cAMP concentrations and
cAMP-dependent protein kinase A. The PTH receptor also activates the calcium protein kinase C pathway, stimulating proliferation of cells in the osteoblastic lineage.

The new molecule teriparatide exerts its anabolic effect at least in part by stimulating the MAPK pathway and, thus, modulating the differentiation, proliferation, and activity of the osteoblasts pool, stimulating differentiation and activation of quiescent lining cells, increasing the lifespan of osteoblasts and osteocytes by inhibiting their apoptosis. Some of these effects seem mediated by direct activation of the essential and early transcription factor Runx2, which plays a pivotal role in the osteoblasts differentiation pattern, likely activating a PKA-dependent increase and/or modulating the expression of cyclins and cyclin-dependent kinase inhibitors important in both pro-survival and pro-differentiating effects of PTH on cells of osteoblast lineage.

Further, teriparatide exerts control of replication, differentiation and survival of osteoblast progenitors by modulating the synthesis and release of local mediators including Wnt, BMPs, TGF-β, IGF-I, fibroblast growth factor-2 (FGF-2) and interleukin-6 (IL-6). Interestingly, recent data have shown that teriparatide, by these mechanisms of action, can counteract the GC-induced effects on bone cells.

Bone levels of IGF-I decreased by GC can be stimulated by PTH, leading to increasing pro-differentiating and pro-survival effects on osteoblasts. More recent studies have also shown that PTH modulates both Wnt and sclerostin expression, which play important, and opposite, roles in the control of bone formation. PTH, in fact, blunts mRNA and protein expression of the secreted osteocytic factor sclerostin, which prevents the binding of Wnt ligands to their receptors, which comprise Frizzled complex with either LRP5 or LRP6, critical for bone formation.

Additionally, GC stimulate the differentiation of stromal cells towards the adipocyte lineage, decreasing the differentiation of progenitors towards bone cell lineages and, thus, contributing to the disruption of bone cell homeostasis. Intermittent PTH inhibits PPARγ transactivation activity, decreasing adipocytic differentiation and leading to an increase in the number of osteoblasts and again antagonizing the deleterious effects of these steroids on the skeleton.

Clinical implications of teriparatide in GIOP

Prophylaxis in patients receiving GC is extremely low. Recently published studies estimate that the proportion of patients receiving some form of osteoporosis prophylaxis is
between 30% and 62%. The use of bone active medication is extremely low among GC users with estimates of just 1.8% of patients using bisphosphonates during the period of follow-up.

Current guidelines for GIOP management recommend bisphosphonates, especially alendronate and risedronate, as first-line agents for GIOP, and guidelines propose the preventive use of bisphosphonates early in the course of GC therapy in high-risk patients.

More recently, efficacy data have demonstrated that teriparatide is an efficacious treatment for patients with GIOP compared with an approved treatment, alendronate. Due to the results obtained in these clinical studies, teriparatide has recently received an indication for GIOP and label indication has also been expanded.

Indeed, it is clear from the mechanisms of actions described above that teriparatide is, to date, the only anabolic molecule that can counteract the deleterious effects of GC on the skeleton, and thus is an efficacious therapy for GIOP.

The first interesting data on the protective role of teriparatide in GIOP have been published by Lane and colleagues, who showed, in a small pilot study, that teriparatide could not only block the GC-induced bone loss, but could even increase spine bone mineral density (BMD) by 12% and femoral neck BMD by a slightly lesser amount.

Interestingly, the same authors measured BMD of the spine every 6 months by dual-energy X-ray absorptiometry (DEXA) and L1 and L2 vertebrae by quantitative computed tomography (QCT) annually. Vertebral cross-sectional area (VCSA) was obtained from the QCT scans and the vertebral compressive strength VCSA was also calculated. After 1 year of human PTH (1–34) treatment, VCSA significantly increased and this result was maintained after treatment was discontinued. Since vertebral fracture risk is related to both bone size and bone mass, the authors speculated that the increase in vertebral size associated with human PTH (1–34) treatment was, at least in part, responsible for increased vertebral bone strength and reduction of fracture risk.

A larger study by Saag and colleagues further demonstrated the efficacy of teriparatide in GIOP. The data were derived from an 18-month randomized, double-blind controlled trial, in which teriparatide was given to women and men with osteoporosis (age 22–89 years) who had received GC for at least 3 months (prednisone equivalent, 5 mg daily or more) and compared with alendronate. The primary outcome was the change in BMD at the lumbar spine, while secondary outcomes included changes in hip BMD, markers of bone turnover, incidence of fractures and safety. The data showed that teriparatide blocked, as already demonstrated, the bone loss induced by GC, but also induced a significant increase in BMD at the lumbar spine (7.2% ± 0.7%) by 6 months (p < 0.001). Even more interestingly, fewer new vertebral fractures were present in the teriparatide group than in the alendronate group (0.6% vs 6.1%, p = 0.004) while the incidence of nonvertebral fractures was similar in the two groups (5.6% vs 3.7%, p = 0.36). In following studies, serum levels of RANKL, OPG, IL-6, and IL-6sR were evaluated at baseline and thereafter for a total of 24 months. Teriparatide caused a rapid and significant increase in serum RANKL within 1 month, remaining elevated throughout the duration of therapy. IL-6 increased significantly within 1 month, but returned to baseline levels more rapidly. In contrast, OPG was mildly suppressed from 6 months after therapy. These data further support the hypothesis that human PTH (1–34) first stimulates osteoblast maturation and function, which in turn leads to osteoclast activation with a consequent gradual rebalancing of bone formation and resorption. The bone mass increase in specific sites might require different lengths of time, as demonstrated in another study which showed maximum increase in bone mass at the hip at least 6 to 12 months after the PTH treatment discontinuation.

The 36-month data, an extension of this published study, was presented at the 2008 meeting of the America Society of Bone and Mineral Research at Montreal, confirming the increase in BMD, the persistence of the significant decrease in fracture risk and, also, the safety of this therapy. In particular, in this 36-month trial GIOP patients treated with teriparatide had greater increases in BMD at the lumbar spine and femoral neck and fewer new vertebral fractures compared with patients treated with alendronate. Furthermore, teriparatide treatment, usually prescribed for 24 months, was well tolerated in the 36-month trial.

In conclusion, the mechanism of action of this new anabolic agent and the clinical data demonstrate that teriparatide can be considered a safe and highly promising therapeutic approach for GIOP.

Acknowledgments
Authors would like to thank Dr Libuse Tauchmanova for helpful discussion.

Disclosures
None of the authors disclose conflicts of interest.
Therapeutics and Clinical Risk Management downloaded from https://www.dovepress.com/ by 54.70.40.11 on 28-Mar-2019

References


59. Rehman Q, Lang T, Arnaud CD, Modin GW, Lane NE. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteopor Int. 2003;14:77–81.
63. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res. 2000;15:944–951.